This was the main objective of the present study, in which we have performed a pharmacogenomic genome-wide association study (GWAS) of treatment response to all the inhibitors of the IL-17A, signaling in a cohort of 88 Greek patients with moderate to severe psoriasis. Here, IL17A is linked to psoriasis.